DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery

Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Procedural Sedation; Regional Anesthesia Block; Orthopedic Surgery

Intervention: Fospropofol disodium (Drug); Fospropofol disodium (Drug); Placebo + Midazolam (Drug); Fentanyl (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Mayo Clinic

Official(s) and/or principal investigator(s):
John B Leslie, MD MBA, Principal Investigator, Affiliation: Mayo Clinic

Summary

How does Lusedra compare with current standard of care (midazolam) for minimal to moderate sedation for regional anesthesia blocks prior to orthopedic surgery?

Clinical Details

Official title: A Prospective Randomized Study to Assess the Efficacy and Safety of Bolus-dose Lusedra (Fospropofol Disodium) 6.5 mg/kg or 10 mg/kg Versus a Placebo (With Midazolam Rescue) for Minimal-to-moderate Sedation in Patients Undergoing Procedural Sedation for Regional Anesthesia Blocks Prior to Orthopedic Surgery

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Percentage of Participants Achieving Sedation Within 4 Minutes

Detailed description: The study overall is aimed at establishing the superiority of a single intravenous bolus-dose of Lusedra for routine use in preoperative regional blocks that avoids deeper levels of sedation and increased risk of nerve damage in an over-sedated individual. The shorter half-life of Lusedra should also demonstrate a superior recovery profile compared to midazolam when used as a rescue comparator. While this study will only enroll patients undergoing regional blocks prior to orthopedic surgery, the clinical utility and value of the larger initial intravenous dosing for Lusedra may be evident for many different monitored anesthesia care anesthetic management situations requiring rapid and effective onset of effects.

Eligibility

Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Undergoing elective orthopedic surgery

- With a regional block prior to surgery

- Able to consent and complete the assessments and procedures

- If female, must be surgically sterile, postmenopausal, or not pregnant or lactating

and using an acceptable method of birth control for at least 1 month prior to surgery with a negative urine pregnancy test at screening

- American Society of Anesthesiologists Physical Classification System status category

P1 to P4 Exclusion Criteria:

- History of allergic reaction or hypersensitivity to any anesthetic agent, opioid, or

benzodiazepine

- Fentanyl citrate injection or midazolam hydrocholoride injection contraindicated

Locations and Contacts

Mayo Clinic, Phoenix, Arizona 85054, United States
Additional Information

Mayo Clinic Clinical Trials

Starting date: February 2011
Last updated: June 25, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017